Virbac: solid 2025 dynamic with annual revenue up +7.9% at CERS3; with strong momentum in key categories and countries

Summary by AI BETAClose X

Virbac reported solid 2025 results with annual revenue reaching €1,465 million, a 7.9% increase at constant exchange rate and scope (CERS), driven by strong companion animal growth of 10.9% and farm animal growth of 6.1%. The USA led performance with 14.7% CERS growth, followed by IMEA and Latin America at 7.5% each. For 2026, Virbac anticipates revenue growth between 5.5% and 7.5% at constant rates and scope, with adjusted recurring operating income around 17%, including the impact of the Thyronorm acquisition.

Disclaimer*

Companies

Virbac SA (0NM7)
UK 100

Latest directors dealings